Smashed Peaches

Drug Research Studies

Bloom Energy (BE) Reaches $9.64 After 6.00% Down Move; Fibrogen (FGEN) Shorts Down By 13.64% – The FinHeadLines

The stock of Bloom Energy Corporation (NYSE:BE) is a huge mover today! The stock decreased 4.15% or $0.42 during the last trading session, reaching $9.64. About 391,894 shares traded. Bloom Energy Corporation (NYSE:BE) has 0.00% since February 11, 2018 and is . It has by 0.00% the S&P500.The move comes after 9 months negative chart setup for the $1.06B company. It was reported on Feb, 11 by Barchart.com. We have $9.06 PT which if reached, will make NYSE:BE worth $63.30M less.

Fibrogen Inc (NASDAQ:FGEN) had a decrease of 13.64% in short interest. FGEN’s SI was 2.46M shares in February as released by FINRA. Its down 13.64% from 2.85M shares previously. With 717,700 avg volume, 3 days are for Fibrogen Inc (NASDAQ:FGEN)’s short sellers to cover FGEN’s short positions. The stock increased 0.53% or $0.3 during the last trading session, reaching $57.28. About 118,731 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has declined 13.72% since February 11, 2018 and is downtrending. It has underperformed by 13.72% the S&P500. Some Historical FGEN News: 09/05/2018 – FIBROGEN 1Q LOSS/SHR 50C, EST. LOSS/SHR 51C; 21/05/2018 – FIBROGEN: PAMREVLUMAB SLOWED IPF DISEASE PROGRESSION IN STUDY; 07/05/2018 – RESOURCE CAPITAL FUND Vl L.P. ANNOUNCES ACQUISITION OF UNITS IN LOS ANDES COPPER LTD; 09/05/2018 – FibroGen 1Q Rev $31.9M; 18/04/2018 – The Andes Summit: More Than Ayahuasca – A Re-Validation of the Cultural Heritage of Ecuador’s Ancient Indigenous Wisdom; 31/05/2018 – ASTELLAS PHARMA INC – ROXADUSTAT WAS WELL TOLERATED IN STUDY; 12/04/2018 – ARGENTINA IS SAID TO PROBE TRADES OF ANDES FOR INSIDER TRADING; 12/04/2018 – $GLPG moving fast into #IPF Ph3 vs. $FGEN still at a snail’s pace; 01/05/2018 – Imperas and Andes Extend Partnership, Delivering Models and Virtual Platforms for Andes RISC-V Cores with New AndeStar V5m; 14/05/2018 – FibroGen Closes Above 200-Day Moving Average: Technicals

Bloom Energy Corporation designs, manufactures, and sells solid-oxide fuel cell systems. The company has market cap of $1.06 billion. It offers Bloom Energy Server, a stationary power generation platform that converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. It currently has negative earnings. The firm was formerly known as Ion America Corp. and changed its name to Bloom Energy Corporation in September 2006.

More notable recent Bloom Energy Corporation (NYSE:BE) news were published by: Seekingalpha.com which released: “Bloom Energy 2018 Q4 – Results – Earnings Call Slides – Seeking Alpha” on February 06, 2019, also Fool.com with their article: “The Marijuana Stock That Wall Street Thinks Will be the Biggest Winner This Year – The Motley Fool” published on February 10, 2019, Fool.com published: “This Could Be the Next Marijuana Stock to Take Off (Hint: It’s Not Canopy Growth) – The Motley Fool” on February 10, 2019. More interesting news about Bloom Energy Corporation (NYSE:BE) were released by: Seekingalpha.com and their article: “The Mobile TeleSystems Plunge – Seeking Alpha” published on February 11, 2019 as well as Seekingalpha.com‘s news article titled: “Ford: Stock Woes; Dividend Next? – Seeking Alpha” with publication date: February 11, 2019.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.87 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.